Cargando…

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction

There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-converting enzyme inhibitor (ACEI) is recommended as a first-line inhibitor of renin-angiotensin syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jae-Geun, Joo, Seung-Jae, Kim, Song-Yi, Choi, Joon-Hyouk, Boo, Ki Yung, Hwang, Jin-Yong, Hur, Seung-Ho, Jeong, Myung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997890/
https://www.ncbi.nlm.nih.gov/pubmed/36893150
http://dx.doi.org/10.1371/journal.pone.0281460
_version_ 1784903352464703488
author Lee, Jae-Geun
Joo, Seung-Jae
Kim, Song-Yi
Choi, Joon-Hyouk
Boo, Ki Yung
Hwang, Jin-Yong
Hur, Seung-Ho
Jeong, Myung Ho
author_facet Lee, Jae-Geun
Joo, Seung-Jae
Kim, Song-Yi
Choi, Joon-Hyouk
Boo, Ki Yung
Hwang, Jin-Yong
Hur, Seung-Ho
Jeong, Myung Ho
author_sort Lee, Jae-Geun
collection PubMed
description There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-converting enzyme inhibitor (ACEI) is recommended as a first-line inhibitor of renin-angiotensin system (RASI) in patients with acute MI (AMI), but ARB is also frequently used to control blood pressure. This study investigated the association of ARB vs. ACEI with the long-term clinical outcomes in hypertensive patients with AMI. Among patients enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH, 4,827 hypertensive patients, who survived the initial attack and were taking ARB or ACEI at discharge, were selected for this study. ARB therapy was associated with higher incidence of 2-year major adverse cardiac events, cardiac death, all-cause death, MI than ACEI therapy in entire cohort. After propensity score-matching, ARB therapy was still associated with higher incidence of 2-year cardiac death (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.20–2.14; P = 0.001), all-cause death (HR, 1.81; 95% CI, 1.44–2.28; P < 0.001), and MI (HR, 1.76; 95% CI, 1.25–2.46; P = 0.001) than the ACEI therapy. It was concluded that ARB therapy at discharge in hypertensive patients with AMI was inferior to ACEI therapy with regard to the incidence of CD, all-cause death, and MI at 2-year. These data suggested that ACEI be a more appropriate RASI than ARB to control BP in hypertensive patients with AMI.
format Online
Article
Text
id pubmed-9997890
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-99978902023-03-10 Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction Lee, Jae-Geun Joo, Seung-Jae Kim, Song-Yi Choi, Joon-Hyouk Boo, Ki Yung Hwang, Jin-Yong Hur, Seung-Ho Jeong, Myung Ho PLoS One Research Article There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-converting enzyme inhibitor (ACEI) is recommended as a first-line inhibitor of renin-angiotensin system (RASI) in patients with acute MI (AMI), but ARB is also frequently used to control blood pressure. This study investigated the association of ARB vs. ACEI with the long-term clinical outcomes in hypertensive patients with AMI. Among patients enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH, 4,827 hypertensive patients, who survived the initial attack and were taking ARB or ACEI at discharge, were selected for this study. ARB therapy was associated with higher incidence of 2-year major adverse cardiac events, cardiac death, all-cause death, MI than ACEI therapy in entire cohort. After propensity score-matching, ARB therapy was still associated with higher incidence of 2-year cardiac death (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.20–2.14; P = 0.001), all-cause death (HR, 1.81; 95% CI, 1.44–2.28; P < 0.001), and MI (HR, 1.76; 95% CI, 1.25–2.46; P = 0.001) than the ACEI therapy. It was concluded that ARB therapy at discharge in hypertensive patients with AMI was inferior to ACEI therapy with regard to the incidence of CD, all-cause death, and MI at 2-year. These data suggested that ACEI be a more appropriate RASI than ARB to control BP in hypertensive patients with AMI. Public Library of Science 2023-03-09 /pmc/articles/PMC9997890/ /pubmed/36893150 http://dx.doi.org/10.1371/journal.pone.0281460 Text en © 2023 Lee et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lee, Jae-Geun
Joo, Seung-Jae
Kim, Song-Yi
Choi, Joon-Hyouk
Boo, Ki Yung
Hwang, Jin-Yong
Hur, Seung-Ho
Jeong, Myung Ho
Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title_full Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title_fullStr Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title_full_unstemmed Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title_short Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
title_sort impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997890/
https://www.ncbi.nlm.nih.gov/pubmed/36893150
http://dx.doi.org/10.1371/journal.pone.0281460
work_keys_str_mv AT leejaegeun impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT jooseungjae impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT kimsongyi impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT choijoonhyouk impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT bookiyung impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT hwangjinyong impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT hurseungho impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT jeongmyungho impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction
AT impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockersonclinicaloutcomesinhypertensivepatientswithacutemyocardialinfarction